AxoGen, Inc Common Stock (NASDAQ:AXGN) gets upgraded to Buy by BTIG Research with a price target of $28.00

ME Staff
-
0

Analyst Ratings For AxoGen, Inc Common Stock (NASDAQ:AXGN)

Today, AxoGen, Inc Common Stock (NASDAQ:AXGN) stock received an upgrade by BTIG Research from Neutral to Buy with a price target of $28.00.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on AxoGen, Inc Common Stock (NASDAQ:AXGN) is Buy with a consensus target price of $38.00 per share, a potential 78.40% upside.

Some recent analyst ratings include

  • 3/25/2019-AxoGen, Inc Common Stock (NASDAQ:AXGN) gets upgraded to Buy by BTIG Research with a price target of $28.00
  • 10/30/2018-AxoGen, Inc Common Stock (NASDAQ:AXGN) had its Outperform rating reiterated by Leerink Swann with a $55.00 price target
  • 2/5/2018-AxoGen, Inc Common Stock (NASDAQ:AXGN) has coverage initiated with a Outperform rating
  • On 11/30/2018 Gregory Gene Freitag, General Counsel, sold 45,000 with an average share price of $33.00 per share and the total transaction amounting to $1,485,000.00.
  • On 11/15/2018 Gregory Gene Freitag, General Counsel, sold 20,000 with an average share price of $32.25 per share and the total transaction amounting to $645,000.00.
  • On 11/14/2018 Karen L Zaderej, CEO, sold 25,000 with an average share price of $33.18 per share and the total transaction amounting to $829,500.00.
  • On 8/14/2018 Amy Mcbride Wendell, Director, bought 5,000 with an average share price of $36.89 per share and the total transaction amounting to $184,450.00.
  • On 5/16/2018 Shawn F Mccarrey, SVP, sold 10,000 with an average share price of $43.47 per share and the total transaction amounting to $434,700.00.
  • On 2/20/2018 Jamie Mark Grooms, Director, sold 63,395 with an average share price of $27.67 per share and the total transaction amounting to $1,754,139.65.
  • On 2/15/2018 Jamie Mark Grooms, CFO, sold 95,712 with an average share price of $26.84 per share and the total transaction amounting to $2,568,910.08.

About AxoGen, Inc Common Stock (NASDAQ:AXGN)
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Recent Trading Activity for AxoGen, Inc Common Stock (NASDAQ:AXGN)
Shares of AxoGen, Inc Common Stock closed the previous trading session at 21,30 +0,89 4,36 % with 20.79 shares trading hands.